LEP and Insulin resistance: EcN expressing acylphosphatidylethanolamines (NAPEs) or GLP-1 analog may have potential as a therapeutic intervention for obesity, leading to the inhibition of weight gain, food intake, adiposity, insulin resistance, and hepatosteatosis reduction and maintaining lower plasma leptin and insulin levels.